vs
Side-by-side financial comparison of American Express (AXP) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $18.9M, roughly 1.1× American Express). American Express runs the higher net margin — 15.7% vs -84.4%, a 100.1% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs -65.2%). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -95.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
AXP vs TRDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $20.6M |
| Net Profit | $3.0M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | — | -106.0% |
| Net Margin | 15.7% | -84.4% |
| Revenue YoY | 11.4% | -65.2% |
| Net Profit YoY | 15.0% | -173.8% |
| EPS (diluted) | — | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.3B | — | ||
| Q1 25 | $9.6B | $20.6M | ||
| Q4 24 | $10.0B | $37.4M | ||
| Q3 24 | $9.7B | $19.6M | ||
| Q2 24 | $9.8B | $94.7M |
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $2.6B | $-17.3M | ||
| Q4 24 | $2.2B | $1.1M | ||
| Q3 24 | $2.5B | $-14.0M | ||
| Q2 24 | $3.0B | $55.0M |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | — | ||
| Q3 25 | 36.7% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 34.6% | -106.0% | ||
| Q4 24 | 27.7% | -15.7% | ||
| Q3 24 | 33.0% | -110.7% | ||
| Q2 24 | 38.6% | 56.4% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 27.9% | — | ||
| Q2 25 | 28.0% | — | ||
| Q1 25 | 26.8% | -84.4% | ||
| Q4 24 | 21.8% | 3.0% | ||
| Q3 24 | 25.8% | -71.7% | ||
| Q2 24 | 30.7% | 58.1% |
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | — | ||
| Q3 25 | $4.14 | — | ||
| Q2 25 | $4.08 | — | ||
| Q1 25 | $3.64 | $-0.42 | ||
| Q4 24 | $3.04 | $-0.20 | ||
| Q3 24 | $3.49 | $-0.35 | ||
| Q2 24 | $4.15 | $1.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $67.8M |
| Total DebtLower is stronger | $60.4M | — |
| Stockholders' EquityBook value | $34.0M | $417.3M |
| Total Assets | $308.9M | $486.5M |
| Debt / EquityLower = less leverage | 1.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $197.0M | — | ||
| Q1 25 | $261.0M | $67.8M | ||
| Q4 24 | $221.0M | $101.2M | ||
| Q3 24 | $120.0M | $78.0M | ||
| Q2 24 | $188.0M | $185.3M |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | — | ||
| Q3 25 | $32.4B | — | ||
| Q2 25 | $32.3B | — | ||
| Q1 25 | $31.2B | $417.3M | ||
| Q4 24 | $30.3B | $428.7M | ||
| Q3 24 | $29.7B | $422.4M | ||
| Q2 24 | $29.5B | $429.9M |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | — | ||
| Q3 25 | $297.6B | — | ||
| Q2 25 | $295.6B | — | ||
| Q1 25 | $282.2B | $486.5M | ||
| Q4 24 | $271.5B | $526.3M | ||
| Q3 24 | $271.0B | $554.6M | ||
| Q2 24 | $272.2B | $582.0M |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $4.8B | $-38.5M | ||
| Q4 24 | $5.8B | $-31.6M | ||
| Q3 24 | $-1.8B | $-24.3M | ||
| Q2 24 | $4.5B | $39.8M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $3.7B | — | ||
| Q1 25 | $4.3B | $-39.7M | ||
| Q4 24 | $5.3B | $-32.2M | ||
| Q3 24 | $-2.3B | $-24.9M | ||
| Q2 24 | $4.0B | $38.8M |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 36.3% | — | ||
| Q1 25 | 45.0% | -192.9% | ||
| Q4 24 | 53.1% | -86.2% | ||
| Q3 24 | -23.3% | -127.3% | ||
| Q2 24 | 40.4% | 41.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | 4.5% | 5.6% | ||
| Q4 24 | 5.0% | 1.7% | ||
| Q3 24 | 4.7% | 3.3% | ||
| Q2 24 | 5.8% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 2.66× | -27.94× | ||
| Q3 24 | -0.72× | — | ||
| Q2 24 | 1.50× | 0.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
TRDA
Segment breakdown not available.
